Search Results: All recruiting trials found

Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.

26 trials found

Imatinib + PDR001
PDR001 Plus Imatinib for Metastatic or Unresectable GIST
1/2
       
Imatinib + Selinexor
Selinexor in Combination With Imatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors. (SeliGIST)
1/2
       
THE-630
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
1/2
       
Famitinib
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
3
       
Imatinib
Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)
3
       
Imatinib
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
3
       
Avelumab + Axitinib
A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy (AXAGIST)
2
       
Imatinib
The Stop-GIST Trial: Discontinuation of Imatinib in Patients With Oligo-metastatic GIST
2
       
Lenvatinib
Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure (LENVAGIST)
2
       
Paclltaxel
Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.
2
       
Regorafenib (SDH)
Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI)
2
       
Temozolomide
Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor
2
       
MAAT
Cognitive Impairment in GIST Patients on Tyrosine Kinase Inhibitor Therapy: Cognitive Behavioral Therapy to Improve Cognitive Symptoms (GIST-MAAT)
0
       
Imatinib + Sunitinib + Regorafenib
GIST: Assessment of Tumor Mutations and TKI Plasma Exposure
       
Surgery
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
       
EDO-S101
Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors
1/2
       
Regorafenib + Avelumab
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)
1/2
       
Rogaratinib
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
2
       
HER-2 B Cell Peptide
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
1
       
HQP1351
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
1
       
Imatinib + Ipilimumab
Ipilimumab and Imatinib Mesylate in Advanced Cancer
1
       
NB003
A Study of NB003 in Patients With Advanced Malignancies
1
       
CS1001 + Regorafenib
A Study of CS1001 in Subjects With Advanced or Refractory Solid Tumors
1/2
       
CB-839
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
2
       
Entrectinib
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)
2
       
LOXO-101
Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors
2